Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application cephalexin tablets, 250mg and 500mg. Aurobindo Pharma’s, Cephalexin Tablets are an AB-rated generic equivalent to the reference listed drug (RLD), Keflet Tablets, manufactured by Eli Lilly and Co.
Cephalexin tablets are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms:
• Respiratory tract infections
• Otitis media
• Skin and skin structure infections
• Bone infections
• Genitourinary tract infections
Cephalexin tablets has an estimated market size of US $26.8 Million for the twelve months ending July 2024, as per IQVIA.
